Λίστα αντικειμένων
Even at low doses, nivolumab maintenance after allo-SCT can cause serious immune-related toxicitiesWe report rapid, unexpected occurrences of grade 3/4 immune-related adverse events ·Nivolumab enhanced the graft-vs-tumor response but more studies are needed to improve tolerability
Presenter: Prof.Spyridonidis
Participants: Dr Liga, Dr Spyridis, Dr Fragopanagou, Dr Vadratsikas
Presenter: Prof.Spyridonidis
Participants: Dr Liga, Dr Spyridis, Dr Fragopanagou, Dr Vadratsikas